AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15661451 — intervention group
Group type: EXPERIMENTAL
Intervention: High TSH values (TSH >= 10 mU/L)
Number of subjects: 64887
Study 15661451 — intervention group
Group type: COMPARATOR
Intervention: Normal TSH values (0.2-4 mU/L)
Number of subjects: 64887
Study 12067084 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture treatment (three times per week for four weeks)
Number of subjects: 30
Study 12067084 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture treatment (three times per week for four weeks)
Number of subjects: 30
Study 12067084 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture treatment
Number of subjects: 30
Study 12067084 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture treatment
Number of subjects: 30
Study 15321137 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 2.5 mg/ml (group B)
Number of subjects: 140
Study 15321137 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.625 mg/ml + sufentanil 1 microg/ml (group BS)
Number of subjects: 140
Study 15321137 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.625 mg/ml + sufentanil 1 microg/ml + epinephrine 1 microg/ml (group BSE)
Number of subjects: 140
Study 15321137 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 140
Study 7734157 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg orally twice a day (Group A)
Number of subjects: 0
Study 7734157 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin drops in saline solution locally twice a day (Group B)
Number of subjects: 0
Study 2291745 — intervention group
Group type: EXPERIMENTAL
Intervention: Test preparation (P)
Number of subjects: 20
Study 2291745 — intervention group
Group type: COMPARATOR
Intervention: Control preparation (R)
Number of subjects: 20
Study 30821548 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate
Number of subjects: 30
Study 30821548 — intervention group
Group type: EXPERIMENTAL
Intervention: Petrolatum jelly
Number of subjects: 30
Study 30821548 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release skin barrier emulsion
Number of subjects: 30
Study 30849105 — intervention group
Group type: EXPERIMENTAL
Intervention: Core training (CT) - 3 extra sessions per week for 8 weeks
Number of subjects: 21
Study 30849105 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) - maintained regular training
Number of subjects: 21
Study 27841726 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention (HBI)
Number of subjects: 100
Study 27841726 — intervention group
Group type: COMPARATOR
Intervention: Specialist clinic-based intervention (CBI)
Number of subjects: 100
Study 25409100 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Eye Movement (REM) sleep
Number of subjects: 58
Study 25409100 — intervention group
Group type: COMPARATOR
Intervention: Non-Rapid Eye Movement (NREM) sleep
Number of subjects: 58
Study 25409100 — intervention group
Group type: COMPARATOR
Intervention: Awake (WAKE)
Number of subjects: 58
Study 22361008 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive intervention with four telephone supporting sessions (weeks 3, 6, 9, and 12)
Number of subjects: 626
Study 22361008 — intervention group
Group type: COMPARATOR
Intervention: Control group with two check calls (weeks 3 and 12)
Number of subjects: 626
Study 22361008 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive intervention group
Number of subjects: 626
Study 22361008 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 626
Study 21594215 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-stage early loaded implants
Number of subjects: 47
Study 21594215 — intervention group
Group type: COMPARATOR
Intervention: 2-stage early loaded implants
Number of subjects: 47
Study 20715726 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid infusion of lactated Ringer's solution (20 ml.kg(‐1), n=40)
Number of subjects: 120
Study 20715726 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% succinylated gelatin solution (500 ml, n=40)
Number of subjects: 120
Study 20715726 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine infusion (1.25 mg.minute(‐1)) plus lactated Ringer's solution (1000 ml, n=40)
Number of subjects: 120
Study 20715726 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid preload
Number of subjects: 120
Study 20715726 — intervention group
Group type: COMPARATOR
Intervention: Colloid preload
Number of subjects: 120
Study 20715726 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine infusion with crystalloid co-load
Number of subjects: 120
Study 20715726 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study 17396039 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan 80 mg/m2 followed by FA 500 mg/m2 and 5-FU 2,000 mg/m2 24 h weekly for 6 weeks
Number of subjects: 55
Study 17396039 — intervention group
Group type: COMPARATOR
Intervention: irinotecan 125 mg/m2 weekly for 4 weeks
Number of subjects: 55
Study 16391436 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 45
Study 16391436 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study 16391436 — intervention group
Group type: EXPERIMENTAL
Intervention: TIL positive patients
Number of subjects: 45
Study 16391436 — intervention group
Group type: EXPERIMENTAL
Intervention: TIL negative patients
Number of subjects: 45
Study 11952192 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral couples therapy (BCT; n = 37)
Number of subjects: 75
Study 11952192 — intervention group
Group type: COMPARATOR
Intervention: Individual-based treatment (IBT; n = 38)
Number of subjects: 75
Study 9892499 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with cutaneous leishmaniasis (CL)
Number of subjects: 0
Study 9892499 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 8561836 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg cycloserine
Number of subjects: 410
Study 8561836 — intervention group
Group type: COMPARATOR
Intervention: 5 mg cycloserine
Number of subjects: 410
Study 8561836 — intervention group
Group type: COMPARATOR
Intervention: 50 mg cycloserine
Number of subjects: 410
Study 8561836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study 2230895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, methotrexate, and fluorouracil (CMF) (n = 193)
Number of subjects: 391
Study 2230895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, methotrexate, and fluorouracil (CMF)
Number of subjects: 391
Study 2230895 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant therapy (Control) (n = 198)
Number of subjects: 391
Study 380838 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (HC 20‐511, 'Zaditen', Sandoz)
Number of subjects: 20
Study 380838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31505724 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-rod group
Number of subjects: 16
Study 31505724 — intervention group
Group type: COMPARATOR
Intervention: Double-rod group
Number of subjects: 16
Study 26821181 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention
Number of subjects: 0
Study 26262795 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone administration (7.5 g of 1% testosterone gel daily for 3 years)
Number of subjects: 308
Study 26262795 — intervention group
Group type: COMPARATOR
Intervention: Placebo (gel packets daily for 3 years)
Number of subjects: 308
Study 26262795 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 308
Study 26262795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study 23595205 — intervention group
Group type: EXPERIMENTAL
Intervention: BA+SB
Number of subjects: 37
Study 23595205 — intervention group
Group type: EXPERIMENTAL
Intervention: BA
Number of subjects: 37
Study 23595205 — intervention group
Group type: EXPERIMENTAL
Intervention: SB
Number of subjects: 37
Study 23595205 — intervention group
Group type: COMPARATOR
Intervention: PL+PL
Number of subjects: 37
Study 20533282 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary vitamin D intake (highest vs lowest quartile)
Number of subjects: 540
Study 20533282 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D levels (highest vs lowest quartile)
Number of subjects: 540
Study 19210644 — intervention group
Group type: EXPERIMENTAL
Intervention: Suplatast tosilate (6 mg/kg daily)
Number of subjects: 53
Study 19210644 — intervention group
Group type: COMPARATOR
Intervention: Ketotifen fumarate (0.06 mg/kg daily)
Number of subjects: 53
Study 16966191 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinks per drinking day (DDD)
Number of subjects: 0
Study 15034704 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin 600 mg once daily for 7 days
Number of subjects: 12
Study 11142548 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment for generalized anxiety disorder (GAD)
Number of subjects: 26
Study 11142548 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control condition
Number of subjects: 26
Study 9284519 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride (100 microns) delivered for 5 min
Number of subjects: 20
Study 9284519 — intervention group
Group type: COMPARATOR
Intervention: Control (before amiloride)
Number of subjects: 20
Study 9284519 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-amiloride response
Number of subjects: 20
Study 8222103 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 8261
Study 3520798 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 371
Study 3520798 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 371
Study 3520798 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 371
Study 31059421 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-guided binocular
Number of subjects: 20
Study 31059421 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-guided monocular
Number of subjects: 20
Study 31059421 — intervention group
Group type: COMPARATOR
Intervention: Naked-eye tests (both monocular and binocular)
Number of subjects: 20
Study 31059421 — intervention group
Group type: EXPERIMENTAL
Intervention: AR tests
Number of subjects: 20
Study 31059421 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocular tests
Number of subjects: 20
Study 31059421 — intervention group
Group type: EXPERIMENTAL
Intervention: Binocular tests
Number of subjects: 20
Study 28579159 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological warm-up (semi-occluded exercises)
Number of subjects: 30
Study 28579159 — intervention group
Group type: COMPARATOR
Intervention: Traditional warm-up (open vowel [a:])
Number of subjects: 30
Study 27143594 — intervention group
Group type: EXPERIMENTAL
Intervention: RYR-NS (red yeast rice, grape-seed, niacinamide, and folic acid)
Number of subjects: 191
Study 27143594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study 24838406 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D3 (100,000 IU once, then 4000 IU/d for 28 weeks; n=201)
Number of subjects: 408
Study 24838406 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=207)
Number of subjects: 408
Study 24838406 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D3
Number of subjects: 408
Study 21974926 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation program using a self-help manual
Number of subjects: 160
Study 21974926 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 160
Study 20370938 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary group (DG) receiving daily 1200 mg Ca and 7.5 microg vitamin D3 for the first 12 months, then 1200 mg Ca and 22.5 microg vitamin D3 for the next 18 months through fortified dairy products
Number of subjects: 66
Study 20370938 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary group (DG)
Number of subjects: 66
Study 20370938 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) receiving neither counselling nor dairy products
Number of subjects: 66
Study 18840700 — intervention group
Group type: EXPERIMENTAL
Intervention: Stuttering treatment efficacy research
Number of subjects: 0
Study 18840700 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-step, semi-automated, Internet-based method
Number of subjects: 0
Study 18840700 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-item checklist
Number of subjects: 0
Study 18840700 — intervention group
Group type: EXPERIMENTAL
Intervention: Existing taxonomy with 136-item checklist
Number of subjects: 0
Study 16365207 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG with cardiopulmonary bypass (CPB)
Number of subjects: 20
Study 16365207 — intervention group
Group type: COMPARATOR
Intervention: Off‐pump (OPCAB) grafting
Number of subjects: 20
Study 12225715 — intervention group
Group type: EXPERIMENTAL
Intervention: Infarct angiography
Number of subjects: 548
Study 12225715 — intervention group
Group type: COMPARATOR
Intervention: Noninfarct angiography
Number of subjects: 548
Study 10217232 — intervention group
Group type: EXPERIMENTAL
Intervention: rBPI21 (4 mg x kg(‐1) x d(‐1) for 2 consecutive days)
Number of subjects: 401
Study 10217232 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equivalent volume by continuous infusion)
Number of subjects: 401
Study 10217232 — intervention group
Group type: EXPERIMENTAL
Intervention: rBPI21
Number of subjects: 401
Study 10217232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study 7884138 — intervention group
Group type: EXPERIMENTAL
Intervention: New ergonomic stand magnifiers
Number of subjects: 39
Study 7884138 — intervention group
Group type: COMPARATOR
Intervention: Commercial stand magnifier
Number of subjects: 39
Study 2223340 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 3
Study 2223340 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 20 mg
Number of subjects: 3
Study 2223340 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 3
Study 2223340 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 3
Study 80219 — intervention group
Group type: EXPERIMENTAL
Intervention: Perhexiline (300 to 400 mg per day)
Number of subjects: 20
Study 30205115 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-guided warfarin dosing (CYP2C9, VKORC1, and CYP4F2)
Number of subjects: 201
Study 30205115 — intervention group
Group type: COMPARATOR
Intervention: Clinical-guided warfarin dosing
Number of subjects: 201
Study 30205115 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-guided warfarin dosing
Number of subjects: 201
Study 27634581 — intervention group
Group type: EXPERIMENTAL
Intervention: Flash sensor‐based glucose monitoring
Number of subjects: 328
Study 27634581 — intervention group
Group type: COMPARATOR
Intervention: Self‐monitoring of blood glucose with capillary strips
Number of subjects: 328
Study 24890623 — intervention group
Group type: EXPERIMENTAL
Intervention: 2L-PEG preparations
Number of subjects: 599
Study 24890623 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-glasses solutions
Number of subjects: 599
Study 24890623 — intervention group
Group type: COMPARATOR
Intervention: 4L-PEG preparations
Number of subjects: 599
Study 22284040 — intervention group
Group type: EXPERIMENTAL
Intervention: CAG + β‐RT
Number of subjects: 108
Study 22284040 — intervention group
Group type: COMPARATOR
Intervention: CAG
Number of subjects: 108
Study 20206571 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dose-rate (PDR) brachytherapy with optimized dose distribution
Number of subjects: 463
Study 20206571 — intervention group
Group type: COMPARATOR
Intervention: Non-optimized PDR brachytherapy
Number of subjects: 463
Study 20206571 — intervention group
Group type: COMPARATOR
Intervention: Iridium wires (traditional treatment)
Number of subjects: 463
Study 18608313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy combined with imipramine
Number of subjects: 137
Study 18608313 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded in vivo exposure treatment combined with imipramine
Number of subjects: 137
Study 18608313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive treatment combined with imipramine
Number of subjects: 137
Study 18608313 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive therapy combined with imipramine
Number of subjects: 137
Study 18608313 — intervention group
Group type: COMPARATOR
Intervention: Cognitive therapy combined with placebo
Number of subjects: 137
Study 18608313 — intervention group
Group type: COMPARATOR
Intervention: Graded in vivo exposure treatment combined with placebo
Number of subjects: 137
Study 18608313 — intervention group
Group type: COMPARATOR
Intervention: Cognitive treatment combined with placebo
Number of subjects: 137
Study 18608313 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy combined with placebo
Number of subjects: 137
Study 18608313 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 137
Study 18608313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 15740994 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Family Intervention Group
Number of subjects: 0
Study 15740994 — intervention group
Group type: COMPARATOR
Intervention: Relatives' Group
Number of subjects: 0
Study 12635365 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV serotype testing using an indirect ELISA (Murex HCV Serotypes 1‐6 Assay)
Number of subjects: 22
Study 12635365 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV serotype testing
Number of subjects: 22
Study 10659548 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg levofloxacin
Number of subjects: 12
Study 10659548 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg levofloxacin
Number of subjects: 12
Study 8680689 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NAME (nonselective NOS inhibitor)
Number of subjects: 15
Study 8680689 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoguanidine (selective inhibitor of inducible NOS)
Number of subjects: 15
Study 1725036 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 35
Study 1725036 — intervention group
Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 35
Study 6851655 — intervention group
Group type: EXPERIMENTAL
Intervention: Amcinonide ointment 0.1 percent twice a day
Number of subjects: 39
Study 6851655 — intervention group
Group type: COMPARATOR
Intervention: Fluocinonide ointment 0.05 percent three times a day
Number of subjects: 39
Study 31792646 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 144
Study 31792646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 30763138 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass Infiltration (GI)
Number of subjects: 150
Study 30763138 — intervention group
Group type: EXPERIMENTAL
Intervention: Sol-Gel Silica Infiltration (SG)
Number of subjects: 150
Study 30763138 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 150
Study 28373993 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 20 mg/day (group A, n = 31)
Number of subjects: 63
Study 28373993 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group B, n = 32)
Number of subjects: 63
Study 26071673 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 62
Study 26071673 — intervention group
Group type: COMPARATOR
Intervention: Low-dose combined oral contraceptive (COC)
Number of subjects: 62
Study 23025591 — intervention group
Group type: EXPERIMENTAL
Intervention: Achyranthes aspera seed supplementation at 0.10% (D1)
Number of subjects: 0
Study 23025591 — intervention group
Group type: EXPERIMENTAL
Intervention: Achyranthes aspera seed supplementation at 0.25% (D2)
Number of subjects: 0
Study 23025591 — intervention group
Group type: EXPERIMENTAL
Intervention: Achyranthes aspera seed supplementation at 0.50% (D3)
Number of subjects: 0
Study 23025591 — intervention group
Group type: COMPARATOR
Intervention: Control diet (D4; no A. aspera supplementation)
Number of subjects: 0
Study 20456821 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberate decision making
Number of subjects: 0
Study 20456821 — intervention group
Group type: EXPERIMENTAL
Intervention: Intuitive decision making
Number of subjects: 0
Study 20456821 — intervention group
Group type: COMPARATOR
Intervention: Distracted decision making
Number of subjects: 0
Study 18382064 — intervention group
Group type: EXPERIMENTAL
Intervention: Group BK3 (butorphanol 2 microg/(kg x h) mixed with ketamine 120 microg/(kg x h))
Number of subjects: 80
Study 18382064 — intervention group
Group type: EXPERIMENTAL
Intervention: Group BK2 (butorphanol 2 microg/(kg x h) mixed with ketamine 90 microg/(kg x h))
Number of subjects: 80
Study 18382064 — intervention group
Group type: EXPERIMENTAL
Intervention: Group BK1 (butorphanol 2 microg/(kg x h) mixed with ketamine 60 microg/(kg x h))
Number of subjects: 80
Study 18382064 — intervention group
Group type: COMPARATOR
Intervention: Group B (butorphanol 3 microg/(kg x h))
Number of subjects: 80
Study 18382064 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study 15692755 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen treatment for 2 years
Number of subjects: 251
Study 15692755 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 251
Study 12010096 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced power Doppler ultrasound
Number of subjects: 53
Study 12010096 — intervention group
Group type: COMPARATOR
Intervention: Unenhanced color Doppler ultrasound
Number of subjects: 53
Study 12010096 — intervention group
Group type: COMPARATOR
Intervention: Biphasic computed tomography (CT)
Number of subjects: 53
Study 12010096 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound (with or without contrast)
Number of subjects: 53
Study 10090432 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin (400 mg oral loading dose followed by 200 mg/d for 10 days)
Number of subjects: 2916
Study 10090432 — intervention group
Group type: COMPARATOR
Intervention: Comparator therapies (erythromycin, cefaclor, ofloxacin, clarithromycin, and ciprofloxacin)
Number of subjects: 2916